TD Private Client Wealth LLC Sells 9,822 Shares of AbbVie Inc. $ABBV

TD Private Client Wealth LLC cut its holdings in AbbVie Inc. (NYSE:ABBV) by 12.6% during the 4th quarter, Holdings Channel reports. The firm owned 68,073 shares of the company’s stock after selling 9,822 shares during the period. TD Private Client Wealth LLC’s holdings in AbbVie were worth $15,554,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of ABBV. Chelsea Counsel Co. bought a new stake in AbbVie during the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC bought a new stake in AbbVie during the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX bought a new stake in AbbVie during the 3rd quarter valued at approximately $31,000. Legacy Wealth Managment LLC ID boosted its position in AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC boosted its position in AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ABBV. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Piper Sandler lifted their price objective on AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research report on Thursday. Morgan Stanley lifted their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Citigroup cut their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Finally, Barclays began coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.43.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably.
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Stock Performance

ABBV stock opened at $210.54 on Monday. The firm has a 50 day moving average price of $210.27 and a 200-day moving average price of $220.05. AbbVie Inc. has a 52-week low of $180.25 and a 52-week high of $244.81. The firm has a market capitalization of $371.97 billion, a price-to-earnings ratio of 103.71, a PEG ratio of 0.73 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period last year, the business earned $2.46 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date was Wednesday, April 15th. AbbVie’s payout ratio is presently 340.89%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.